NASDAQ:RNA Avidity Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $14.48 -0.07 (-0.48%) (As of 06/28/2022 11:10 AM ET) Add Compare Share Today's Range$14.32▼$14.7750-Day Range$11.18▼$18.2852-Week Range$10.89▼$29.59Volume822 shsAverage Volume489,295 shsMarket Capitalization$720.52 millionP/E RatioN/ADividend YieldN/APrice Target$49.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Stock Forecast (MarketRank)Overall MarketRank™2.03 out of 5 starsMedical Sector569th out of 1,436 stocksPharmaceutical Preparations Industry255th out of 687 stocksAnalyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $49.50, Avidity Biosciences has a forecasted upside of 240.9% from its current price of $14.52.Amount of Analyst CoverageAvidity Biosciences has received no research coverage in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesAvidity Biosciences has received 112 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvidity Biosciences has received 70 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvidity Biosciences has received 61.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avidity Biosciences and other stocks. Vote “Outperform” if you believe RNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders16.08% of the stock of Avidity Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.12% of the stock of Avidity Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avidity Biosciences (NASDAQ:RNA)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More RNA Stock News HeadlinesJune 17, 2022 | nasdaq.comAvidity : Preclinical Results Support AOC 1020 For Facioscapulohumeral Muscular Dystrophy TreatmentJune 17, 2022 | finance.yahoo.comAvidity Biosciences Supports World Facioscapulohumeral Muscular Dystrophy (FSHD) Day and Presents Preclinical Data from FSHD ProgramJune 12, 2022 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Stock Price Down 8.2%June 9, 2022 | finance.yahoo.comAvidity Biosciences Announces Upcoming Presentations at the 29th Annual FSHD Society International Research CongressJune 9, 2022 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Up to $12.65May 30, 2022 | finance.yahoo.comWall Street Analysts Believe Avidity Biosciences, Inc. (RNA) Could Rally 242%: Here's is How to TradeMay 11, 2022 | finance.yahoo.comAvidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue EstimatesMay 10, 2022 | finance.yahoo.comAvidity Biosciences Reports First Quarter 2022 Financial Results and Recent HighlightsMay 9, 2022 | finance.yahoo.comInhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue EstimatesMarch 29, 2022 | finance.yahoo.comAvidity Biosciences Announces Upcoming Presentations at the American Academy of Neurology 2022 Annual MeetingMarch 7, 2022 | benzinga.comAvidity Biosciences Earnings Perspective: Return On Capital EmployedMarch 7, 2022 | finance.yahoo.comAvidity Biosciences Announces Upcoming Presentations at the 2022 MDA Clinical & Scientific ConferenceMarch 1, 2022 | benzinga.comAvidity Biosciences: Q4 Earnings InsightsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees125Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today6/28/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$49.50 High Stock Price Forecast$59.00 Low Stock Price Forecast$36.00 Forecasted Upside/Downside+241.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.910010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118.01 million Net Margins-1,525.48% Pretax Margin-1,525.48% Return on Equity-36.26% Return on Assets-32.81% Debt Debt-to-Equity RatioN/A Current Ratio13.09 Quick Ratio13.09 Sales & Book Value Annual Sales$9.33 million Price / Sales77.23 Cash FlowN/A Price / Cash FlowN/A Book Value$8.13 per share Price / Book1.78Miscellaneous Outstanding Shares49,760,000Free Float41,761,000Market Cap$720.52 million OptionableNot Optionable Beta1.35 Avidity Biosciences Frequently Asked Questions Should I buy or sell Avidity Biosciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avidity Biosciences stock. View analyst ratings for Avidity Biosciences or view top-rated stocks. What is Avidity Biosciences' stock price forecast for 2022? 4 analysts have issued 12 month price objectives for Avidity Biosciences' shares. Their RNA stock forecasts range from $36.00 to $59.00. On average, they anticipate Avidity Biosciences' share price to reach $49.50 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price. View analysts' price targets for Avidity Biosciences or view top-rated stocks among Wall Street analysts. How has Avidity Biosciences' stock price performed in 2022? Avidity Biosciences' stock was trading at $23.77 on January 1st, 2022. Since then, RNA stock has decreased by 39.1% and is now trading at $14.48. View the best growth stocks for 2022 here. When is Avidity Biosciences' next earnings date? Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Avidity Biosciences. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) issued its earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The biotechnology company had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.50 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 36.26% and a negative net margin of 1,525.48%. View Avidity Biosciences' earnings history. Who are Avidity Biosciences' key executives? Avidity Biosciences' management team includes the following people: Dr. Troy Edward Wilson J.D., Ph.D., Co-Founder & Chairman (Age 53, Pay $65k)Ms. Sarah Boyce, Pres, CEO & Director (Age 50, Pay $1M)Mr. Michael F. MacLean, CFO & Chief Bus. Officer (Age 56, Pay $650.38k)Dr. W. Michael Flanagan Ph.D., Chief Technical Officer (Age 60, Pay $1M)Dr. Arthur A. Levin Ph.D., Chief Scientific Officer (Age 68, Pay $662.86k)Mr. Joseph T. Baroldi, Consultant (Age 43, Pay $642.43k)Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.sDr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 72)Ms. Kathleen Gallagher, Sr. VP of Corp. Communications & Investor RelationsDr. John W. Wallen III, VP of Intellectual Property, Gen. Counsel & Sec. (Age 64) Who are some of Avidity Biosciences' key competitors? Some companies that are related to Avidity Biosciences include PTC Therapeutics (PTCT), Indivior (INVVY), Corcept Therapeutics (CORT), CureVac (CVAC), Pacira BioSciences (PCRX), Insmed (INSM), Arvinas (ARVN), EQRx (EQRX), ACADIA Pharmaceuticals (ACAD), HUTCHMED (HCM), Schrödinger (SDGR), Sage Therapeutics (SAGE), Global Blood Therapeutics (GBT), ChemoCentryx (CCXI) and OPKO Health (OPK). View all of RNA's competitors. What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT). When did Avidity Biosciences IPO? (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. What is Avidity Biosciences' stock symbol? Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA." Who are Avidity Biosciences' major shareholders? Avidity Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Aaron Wealth Advisors LLC (8.01%), BlackRock Inc. (6.56%), Vanguard Group Inc. (4.62%), RA Capital Management L.P. (4.36%), State Street Corp (3.30%) and Wellington Management Group LLP (2.28%). Company insiders that own Avidity Biosciences stock include Arthur A Levin and Rtw Investments, Lp. View institutional ownership trends for Avidity Biosciences. Which major investors are selling Avidity Biosciences stock? RNA stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Bank of America Corp DE, Citigroup Inc., BlackRock Inc., Harbor Capital Advisors Inc., JPMorgan Chase & Co., Metropolitan Life Insurance Co NY, and Northern Trust Corp. View insider buying and selling activity for Avidity Biosciences or view top insider-selling stocks. Which major investors are buying Avidity Biosciences stock? RNA stock was acquired by a variety of institutional investors in the last quarter, including Aaron Wealth Advisors LLC, RA Capital Management L.P., Vanguard Group Inc., State Street Corp, Dimensional Fund Advisors LP, Walleye Capital LLC, Walleye Capital LLC, and Wellington Management Group LLP. View insider buying and selling activity for Avidity Biosciences or or view top insider-buying stocks. How do I buy shares of Avidity Biosciences? Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avidity Biosciences' stock price today? One share of RNA stock can currently be purchased for approximately $14.48. How much money does Avidity Biosciences make? Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $720.52 million and generates $9.33 million in revenue each year. The biotechnology company earns $-118.01 million in net income (profit) each year or ($2.910010) on an earnings per share basis. How many employees does Avidity Biosciences have? Avidity Biosciences employs 125 workers across the globe. How can I contact Avidity Biosciences? Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for Avidity Biosciences is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected]. This page (NASDAQ:RNA) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
